Organ Transport Forecast Rises to $750M-$760M
Medical logistics operators should read the raised comparable range as a signal of stronger case-volume demand heading into next year.
Updated on Nov. 7, 2026 in Healthcare

TransMedics Group set its 2026 revenue guidance at $764 million to $774 million, a range that includes approximately $14 million from its PAD Aviation acquisition. Excluding PAD Aviation, the comparable forecast is $750 million to $760 million for operators tracking organ transplant logistics and medical-transport demand.
Why it matters
The forecast raises both ends of the comparable range from the prior $737 million to $757 million, signaling stronger expected demand for its organ-transport services. Management tied the upgrade to record third-quarter 2026 performance, which means healthcare logistics operators should watch whether case-volume growth holds into the next year.
The new guidance of $764 million to $774 million includes roughly $14 million from PAD Aviation, leaving a comparable range of $750 million to $760 million. That comparable range sits $13 million higher at the low end and $3 million higher at the high end than the prior $737 million to $757 million forecast.
The players
TransMedics Group
A medical technology company that operates an organ-transport logistics network using its proprietary care system to move donor organs for transplant.
PAD Aviation
An aviation services provider whose business was folded into TransMedics' 2026 guidance, adding roughly $14 million in expected revenue.
The details
TransMedics sets its guidance as a range, and the 2026 figures include an acquired contribution from PAD Aviation that is reported separately from the core business. Stripping out that roughly $14 million gives the comparable forecast of $750 million to $760 million, which is the figure to compare against the earlier estimate. The company's third quarter of 2026 was its strongest ever for both revenue and case volume, which is the operating basis for the higher range.
Timeline
Q3 2026: Strongest revenue and case-volume quarter in company history.
November 7, 2026: Revenue guidance for 2026 was set at $764 million to $774 million, including PAD Aviation.
Market Landscape
The upward revision builds on the company's own prior comparable guidance of $737 million to $757 million, rather than on an external benchmark the source provides. The stub does not describe competitor guidance or an industry-wide trend, so the story's competitive placement rests on TransMedics' own forecast history.
Operators in healthcare logistics and medical transport should note that the raised comparable range signals stronger demand for time-sensitive organ transport. Procurement and finance teams with exposure to this sector should review how the PAD Aviation contribution is being booked against the core comparable figures.
The takeaway
Growth in case volume, not only pricing, is what drove the higher forecast, so operators should track volume metrics in upcoming quarters. Watch whether PAD Aviation's roughly $14 million contribution is reported separately from the comparable business in future filings, since that split determines how much of the growth is organic.
Further reading
For broader context on how medical logistics and transplant-supply businesses are shaping the sector, explore our Healthcare coverage.




